RNXT
Price:
$0.95
Market Cap:
$34.82M
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Industry
Biotechnology
IPO Date
2021-08-26
Stock Exchange
NASDAQ
Ticker
RNXT
According to RenovoRx, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.61. This represents a change of 25.49% compared to the average of 6.86 of the last 4 quarters.
The mean historical Current Ratio of RenovoRx, Inc. over the last ten years is 5.43. The current 8.61 Current Ratio has changed 15.75% with respect to the historical average. Over the past ten years (40 quarters), RNXT's Current Ratio was at its highest in in the September 2021 quarter at 29.06. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
5.43
Median
3.46
Minimum
0.47
Maximum
17.36
Discovering the peaks and valleys of RenovoRx, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.62%
Maximum Annual Current Ratio = 17.36
Minimum Annual Increase = -83.43%
Minimum Annual Current Ratio = 0.47
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 4.10 | 228.66% |
| 2023 | 1.25 | -81.07% |
| 2022 | 6.59 | -62.02% |
| 2021 | 17.36 | 3.62% |
| 2020 | 0.47 | -83.43% |
The current Current Ratio of RenovoRx, Inc. (RNXT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.98
5-year avg
5.95
10-year avg
5.43
RenovoRx, Inc.’s Current Ratio is greater than Elutia Inc. (0.44), greater than Lantern Pharma Inc. (3.52), greater than Reviva Pharmaceuticals Holdings, Inc. (0.90), greater than MAIA Biotechnology, Inc. (2.19), greater than Annovis Bio, Inc. (6.11), greater than Tvardi Therapeutics, Inc. (3.48), greater than Celularity Inc. (0.16), greater than CalciMedica, Inc. (4.04), greater than BioAtla, Inc. (0.54), greater than PolyPid Ltd. (2.28),
| Company | Current Ratio | Market cap |
|---|---|---|
| 0.44 | $29.45M | |
| 3.52 | $42.17M | |
| 0.90 | $40.31M | |
| 2.19 | $44.44M | |
| 6.11 | $91.48M | |
| 3.48 | $39.21M | |
| 0.16 | $47.46M | |
| 4.04 | $65.85M | |
| 0.54 | $49.86M | |
| 2.28 | $40.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RenovoRx, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RenovoRx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is RenovoRx, Inc.'s Current Ratio?
How is the Current Ratio calculated for RenovoRx, Inc. (RNXT)?
What is the highest Current Ratio for RenovoRx, Inc. (RNXT)?
What is the 3-year average Current Ratio for RenovoRx, Inc. (RNXT)?
What is the 5-year average Current Ratio for RenovoRx, Inc. (RNXT)?
How does the current Current Ratio for RenovoRx, Inc. (RNXT) compare to its historical average?